Human Cytomegalovirus miR-US5-2 Downregulation of GAB1 Regulates Cellular Proliferation and UL138 Expression through Modulation of Epidermal Growth Factor Receptor Signaling Pathways

Human Cytomegalovirus miR-US5-2 Downregulation of GAB1 Regulates Cellular Proliferation and UL138 Expression through Modulation of Epidermal Growth Factor Receptor Signaling Pathways

Regulation of the epidermal growth factor (EGF) receptor (EGFR) signaling is essential for the replication of human cytomegalovirus (HCMV) and the latency and reactivation in CD34 + hematopoietic progenitor cells. HCMV microRNAs (miRNAs) provide a means to modulate the signal is activated by EGF through targeting EGFR signaling pathway components.

Here, we show that miR-US5-2 HCMV immediate critical downregulates EGFR GAB1 adapter proteins that mediate sustained activation and signals through phosphatidylinositol 3-kinase (PI3K) and MEK / extracellular signal-regulated kinase (ERK) pathway and cell proliferation in response to EGF. UL138 HCMV expression is regulated by the transcription factor early growth response gene 1 (EGR1) downstream of EGFR-induced MEK / ERK signaling. We show that by targeting GAB1 and smoothes the MEK / ERK signaling, mir-US5-2 indirectly regulating the expression EGR1 and UL138, which implicates critical miRNA regulation latency.IMPORTANCE HCMV Human cytomegalovirus (HCMV) causes significant illness in immunocompromised individuals, including transplant patients.

HCMV establishes latency in the hematopoietic stem cells in the bone marrow. The mechanisms that regulate the latency and reactivation of viral replication is complex and not fully understood. HCMV-encoded miRNAs are small regulatory RNA that reduces expression of the protein. In this study, we found that HCMV miRNA miR-US5-2 targeting the epidermal growth factor receptor (EGFR) protein GAB1 adapter that directly affect downstream cellular signaling pathways activated by EGF.

As a result, mir-US5-2 block EGF-mediated proliferation of human fibroblasts. early growth response gene 1 (EGR1) is a transcription factor activated by EGFR signaling that regulates the expression of HCMV UL138. We show that miR-UL138 US5-2 regulates expression via downregulation GAB1-mediated signaling pathways that lead to the expression of EGR1. These data demonstrate that miR-US5-2, through downregulation of GAB1, can play an important role during the reactivation from latency by reducing the proliferation and expression of UL138.

 Human Cytomegalovirus miR-US5-2 Downregulation of GAB1 Regulates Cellular Proliferation and UL138 Expression through Modulation of Epidermal Growth Factor Receptor Signaling Pathways
Human Cytomegalovirus miR-US5-2 Downregulation of GAB1 Regulates Cellular Proliferation and UL138 Expression through Modulation of Epidermal Growth Factor Receptor Signaling Pathways

early diagnosis and successful treatment of cytomegalovirus peritonitis in children with primary nephrotic syndrome: a case series and review of the literature

Cytomegalovirus (CMV) is a major pathogen in immunocompromised population and CMV infections in immunocompromised patients cause of morbidity and mortality are quite large. Common clinical manifestations of CMV infection is pneumonia, hepatitis, colitis and so on, while CMV without intestinal perforation peritonitis rarely occurs. Reviewing the literature, CMV peritonitis in patients with nephrotic syndrome (NS) has not been reported. Only four cases of peritonitis CMV without bowel perforation reported in adults with other illnesses.

Two cases were diagnosed by reverse-transcription polymerase chain reaction (RT-PCR) of ascites while two other cases with histopathological examination of peritoneal tissue. We report four cases of primary nephrotic syndrome complicated with CMV peritonitis. Four cases were all diagnosed by RT-PCR from ascites (659-455000 copies / mL).

AASDHPPT 3'UTR Luciferase Stable Cell Line

TU000028 1.0 ml
EUR 1825.2

Aasdhppt 3'UTR Luciferase Stable Cell Line

TU200027 1.0 ml Ask for price

Oct4 CR4-pGreenFire Response Reporter (virus)

SR20070-VA-1 >2 x 10^6 IFUs
EUR 670

AASDHPPT 3'UTR GFP Stable Cell Line

TU050028 1.0 ml
EUR 1825.2

Aasdhppt 3'UTR GFP Stable Cell Line

TU250027 1.0 ml Ask for price

Rat NSE Differentiation Reporter (pGreenZeo, Virus)

SR10024VA-1 >2 x 10^6 IFUs
EUR 691

Human GFAP Differentiation Reporter (pRedZeo, Virus)

SR10051VA-1 >2 x 10^6 IFUs
EUR 691

NFAT Reporter (Luc) - Jurkat Cell Line

60621 2 vials
EUR 2295
Description: The NFAT Reporter - Jurkat Cell Line contains a firefly luciferase gene under the control of the_x000D_NFAT response element stably integrated into Jurkat cells. This cell line has been validated for_x000D_response to thapsigargin, ionomycin, and phorbol 12-myristate 13-acetate (PMA). It is useful as_x000D_a control cell line for other NFAT reporter cell lines expressing various immune checkpoint_x000D_receptors.

GAL4 Reporter (Luc)-HEK293 Cell Line

60656 2 vials
EUR 1095
Description: The GAL4 Reporter (Luc) - HEK293 Cell Line contains a firefly luciferase gene under the control of a multimerized GAL4 upstream activation sequence (UAS) stably integrated into HEK293 cells. The cell line does not contain any exogenous activators of the GAL4 reporter and can be used alongside BPS Cat. #60655 as a control.

Mouse MBP Differentiation Reporter (pGreenZeo, Virus)

SR10026VA-1 >2 x 10^6 IFUs
EUR 691

Human LCK Differentiation Reporter (pGreenZeo, Virus)

SR10032VA-1 >2 x 10^6 IFUs
EUR 691

Human B29 Differentiation Reporter (pGreenZeo, Virus)

SR1004VA-1 >2 x 10^6 IFUs
EUR 691

Mouse B29 Differentiation Reporter (pGreenZeo, Virus)

SR1005VA-1 >2 x 10^6 IFUs
EUR 691

Mouse CD8 Differentiation Reporter (pGreenZeo, Virus)

SR1006VA-1 >2 x 10^6 IFUs
EUR 691

Human CD2 Differentiation Reporter (pGreenZeo, Virus)

SR1009VA-1 >2 x 10^6 IFUs
EUR 691

Mouse Actc Differentiation Reporter (pGreenZeo, Virus)

SR10010VA-1 >2 x 10^6 IFUs
EUR 691

Human GFAP Differentiation Reporter (pGreenZeo, Virus)

SR10015VA-1 >2 x 10^6 IFUs
EUR 691

Mouse GFAP Differentiation Reporter (pGreenZeo, Virus)

SR10016VA-1 >2 x 10^6 IFUs
EUR 691

Mouse EMR1 Differentiation Reporter (pGreenZeo, Virus)

SR10018VA-1 >2 x 10^6 IFUs
EUR 691

Mouse CD44 Differentiation Reporter (pGreenZeo, Virus)

SR10020VA-1 >2 x 10^6 IFUs
EUR 691

Human BM88 Differentiation Reporter (pGreenZeo, Virus)

SR10021VA-1 >2 x 10^6 IFUs
EUR 691

Rat Nestin Differentiation Reporter (pGreenZeo, Virus)

SR10034VA-1 >2 x 10^6 IFUs
EUR 691

Mouse ALBP Differentiation Reporter (pGreenZeo, Virus)

SR10036VA-1 >2 x 10^6 IFUs
EUR 691

Human NGN3 Differentiation Reporter (pGreenZeo, Virus)

SR10037VA-1 >2 x 10^6 IFUs
EUR 691

Human PDX1 Differentiation Reporter (pGreenZeo, Virus)

SR10039VA-1 >2 x 10^6 IFUs
EUR 691

Mouse PDX1 Differentiation Reporter (pGreenZeo, Virus)

SR10040VA-1 >2 x 10^6 IFUs
EUR 691

Human MAP2 Differentiation Reporter (pGreenZeo, Virus)

SR10047VA-1 >2 x 10^6 IFUs
EUR 691

Human ACTC Differentiation Reporter (pGreenZeo, Virus)

SR10049VA-1 >2 x 10^6 IFUs
EUR 691

Human NKX2.5 Differentiation Reporter (pGreenZeo, virus)

SR10067VA-1 >2 x 10^6 IFUs
EUR 691

Mouse CD68 Differentiation Reporter (pGreenZeo, Virus)

SR1008VA-1 >2 x 10^6 IFUs
EUR 691

Human Tnnt2 Differentiation Reporter (pGreenZeo, Virus)

SR10012VA-1 >2 x 10^6 IFUs
EUR 691

Mouse Tnnt2 Differentiation Reporter (pGreenZeo, Virus)

SR10013VA-1 >2 x 10^6 IFUs
EUR 691

Mouse SM22a Differentiation Reporter (pGreenZeo, Virus)

SR10014VA-1 >2 x 10^6 IFUs
EUR 691

Human CD11b Differentiation Reporter (pGreenZeo, Virus)

SR10017VA-1 >2 x 10^6 IFUs
EUR 691

Mouse GAD67 Differentiation Reporter (pGreenZeo, Virus)

SR10023VA-1 >2 x 10^6 IFUs
EUR 691

Human Opsin Differentiation Reporter (pGreenZeo, Virus)

SR10027VA-1 >2 x 10^6 IFUs
EUR 691

Human FABP7 Differentiation Reporter (pGreenZeo, Virus)

SR10048VA-1 >2 x 10^6 IFUs
EUR 691

Mouse Col2a1 Differentiation Reporter (pGreenZeo, Virus)

SR1001VA-1 >2 x 10^6 IFUs
EUR 691

Mouse Camk2a Differentiation Reporter (pGreenZeo, Virus)

SR10022VA-1 >2 x 10^6 IFUs
EUR 691

Human Nestin Differentiation Reporter (pGreenZeo, Virus)

SR10035VA-1 >2 x 10^6 IFUs
EUR 691

STAT5 Reporter (Luc) - Ba/F3 Cell line

79772 2 vials
EUR 2275
Description: The STAT5 Reporter (Luc)-Ba/F3 cell line is designed for monitoring STAT5 signal transduction pathways. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by cytokines or growth factors, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.

IRF Reporter (Luc) - THP-1 Cell line

79858 2 vials
EUR 1810
Description: The Interferon Regulatory Factor (IRF) reporter (Luc)-THP-1 cell line is designed to study the activation and signaling of Cytosolic DNA Sensors (CDS) in human monocytic cell line THP-1. It contains a firefly luciferase gene driven by multimerized ISRE (Interferon Stimulated Response Element) located upstream of the minimal TATA promoter. _x000D_The cGAS-STING pathway acts to detect cytosolic DNA and induce an immune response. Briefly, upon binding DNA, the protein cGAS (cyclic GMP-AMP Synthase) triggers reaction of GTP and ATP to form cGAMP. cGAMP binds to STING (Stimulator of Interferon Genes) which triggers phosphorylation of IRF3 via TBK1. IRF3 can then bind to interferon-stimulated responsive elements (ISRE) in the nucleus and leads to IFN-α/β production. The IRF reporter (Luc)-THP-1 cell line is highly responsive to STING and CDS ligands.

Human Insulin Differentiation Reporter (pGreenZeo, Virus)

SR10028VA-1 >2 x 10^6 IFUs
EUR 691

Aasdhppt/ Rat Aasdhppt ELISA Kit

ELI-11895r 96 Tests
EUR 1063.2

Mouse Myogenin Differentiation Reporter (pGreenZeo, Virus)

SR10050VA-1 >2 x 10^6 IFUs
EUR 691

NF-κB Reporter (Luc) - HCT116 Cell Line

60623 2 vials
EUR 1095
Description: NF-B luciferase reporter construct is stably integrated into the genome of HCT-116 cells. The
firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of
the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors
bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase/HCT-116 cell line is suitable for monitoring the activity of NF-κB signaling
in response to stimulants such as the cytokines TNF and IL-1β, pathogen-associated
molecular pattern (PAMP) (i.e. flagellin) or endogenous damage-associated molecular pattern
(DAMP) molecules (i.e. NOD1 ligand) (see application references). It is also suitable for
establishing cell-based screens for inhibitors that target specific NF-κB stimulating molecules.
This cell line can be further modified to allow investigation of downstream NF-κB activities as a
result of targeted genetic mutation(s).

NF-κB reporter (Luc) - HEK293 Cell line

60650 2 vials
EUR 1365
Description: The NF-κB reporter (Luc) HEK293 cell line is designed to monitor nuclear factor Kappa B (NF-κB) activity. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or agonists of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. The cell line has been functionally validated in response to human TNF-α, IL-1β, and IL-17.

NF-kB reporter (Luc) - HEK293 Cell line

GWB-PS76F8 2X10(6)cells Ask for price

Human Osteocalcin Differentiation Reporter (pGreenZeo, Virus)

SR1003VA-1 >2 x 10^6 IFUs
EUR 691

Mouse IBA-1 Differentiation Reporter (pGreenZeo, Virus)

SR10019VA-1 >2 x 10^6 IFUs
EUR 691

Human SPP-1 Differentiation Reporter (pGreenZeo, Virus)

SR1002VA-1 >2 x 10^6 IFUs
EUR 691

Human MLC-2v Differentiation Reporter (pGreenZeo, Virus)

SR10011VA-1 >2 x 10^6 IFUs
EUR 691

NF- κB Reporter (Luc) - Raw 264.7 Cell line

79978 2 vials
EUR 2045
Description: The NF-κB reporter (Luc)-Raw 264.7 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.

Human GFAP Differentiation Reporter (pGreenZeo, Virus) Puro

SR10015VA-P >2 x 10^6 IFUs
EUR 691

Human HLA-DRa Differentiation Reporter (pGreenZeo, Virus)

SR1007VA-1 >2 x 10^6 IFUs
EUR 691

NF- κB Reporter (Luc) - THP-1 Cell Line

79645 2 vials
EUR 1900
Description: The NF-κB reporter (Luc)-THP-1 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.

Human Keratin 14 Differentiation Reporter (pGreenZeo, Virus)

SR10038VA-1 >2 x 10^6 IFUs
EUR 691

PAI-1 Reporter (Luc) - Mv1 Lu Cell Line

60544 2 vials
EUR 3595
Description: PAI-1 Reporter (Luc)-Mv1 Lu cell line is designed for monitoring transforming growth factor β (TGF-β)-induced plasminogen activator inhibitor-1 (PAI-1) expression. Transforming growth factor-β (TGF-β) is a potent regulator of cellular differentiation, proliferation, migration, and protein expression._x000D__x000D_PAI-1 Reporter (Luc) -Mv1 Lu cell line contains a firefly luciferase gene under the control of PAI-1 responsive elements stably integrated into Mv1 Lu (NBL-7) cells, showing TGF-β pathway response. This cell line is validated for the TGF-β response to the induction of PAI-1 gene expression through luciferase activity. _x000D_

Bald Lentiviral Pseudovirion (Luc-eGFP Dual Reporter)

79988 500 µl x 2
EUR 795
Description: The bald lentiviral pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) as the reporters, driven by a CMV promoter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors._x000D_

NF-κB reporter (Luc) - NIH/3T3 Cell line

79469 2 vials
EUR 1900
Description: The NF-κB reporter (Luc)-NIH/3T3 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.

NF-κB Reporter (Luc) - CHO-K1 Cell Line

60622 2 vials
EUR 1095
Description: An NF-κB luciferase reporter construct is stably integrated into the genome of CHO-K1 cells. The firefly luciferase gene is controlled by the NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase / CHO-K1 cell line is suitable for monitoring the activity of NF-κB transcription factor through luminescence readout.). This cell line responds to human cytokine IL-1β, responds moderately to human TNF, and does not respond to human IFN-λ (2 µg/ml). Reducing the amount of serum during incubation period may increase the sensitivity to cytokines. Since CHO-K1 cells do not express endogenous human proteins, this cell line provides an excellent platform to enable exogenous expression of a protein of interest to study its downstream effect on NF-κB signaling.

AASDHPPT

enz-008 5µg
EUR 60
Description: Recombinant Human Aminoadipate-Semialdehyde Dehydrogenase-Phosphopantetheinyl Transferase

AASDHPPT

CSB-CL865121HU1 10 μg plasmid + 200μl Glycerol Ask for price

AASDHPPT

CSB-CL865121HU2 10 μg plasmid + 200μl Glycerol Ask for price

STAT3 Reporter (Luc) - HEK293 Cell line (Puromycin)

79800-P 2 vials
EUR 3730
Description: The STAT3 Reporter (Luc)-HEK293 cell line is designed for monitoring STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines and growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.

Lentiviral Dual Reporter: CMV-GFP-T2A-Luciferase pre-packaged virus

BLIV101VA-1 >2 x10^6 IFUs
EUR 722

Lentiviral Dual Reporter: UBC-RFP-T2A-Luciferase pre-packaged virus

BLIV200VA-1 >2 x10^6 IFUs
EUR 722

Foxp3 Reporter (Luc) - Jurkat Recombinant Cell Line

60628 2 vials
EUR 7645
Description: Human Foxp3 luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by a human Foxp3 promoter and an enhancer-like conserved noncoding sequence upstream of the Foxp3 promoter.

Mouse Alpha-Tubulin Differentiation Reporter (pGreenZeo, Virus)

SR10025VA-1 >2 x 10^6 IFUs
EUR 691

Human Doublecortin (DCX) Differentiation Reporter (pGreenZeo, Virus)

SR10041VA-1 >2 x 10^6 IFUs
EUR 691

NF-κB Reporter (Luc) - A549 Stable Cell Line

60625 2 vials
EUR 1915
Description: NF-κB luciferase reporter construct is stably integrated into the genome of A549 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.

STAT5 Reporter (Luc)- U937 Cell Line (GM-CSF)

79941 2 vials
EUR 1980
Description: The STAT5 Reporter (Luc)-U937 cell line is designed for monitoring STAT5 signal transduction pathway in the U937 cell line. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by GM-CSF, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.

Rev-A3-GFP/Luc HIV Reporter Cells

HRC-3 1 vial of 5x10⁶ cells
EUR 1800

Lentiviral Triple Reporter: CMV-Luciferase-RFP-TK pre-packaged virus

BLIV102VA-1 >2 x10^6 IFUs
EUR 722

Lentiviral Triple Reporter: UBC-Luciferase-RFP-TK pre-packaged virus

BLIV202VA-1 >2 x10^6 IFUs
EUR 722

Lentiviral Triple Reporter: MSCV-Luciferase-RFP-TK pre-packaged virus

BLIV302VA-1 >2 x10^6 IFUs
EUR 722

Rev-CEM-GFP/Luc HIV Reporter Cells

HRC-5 1 vial of 5x10⁶ cells
EUR 1500

Sox2 SRR2-pGreenFire Response Reporter, pre-packaged virus

SR20071-VA-1 >2 x 10^6 IFUs
EUR 670

Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)

78172-1 100 µl
EUR 835
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I
W152C
L452R
D614G

Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)

78172-2 500 µl x 2
EUR 4195
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I
W152C
L452R
D614G

Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)

78204-1 100 µl
EUR 835
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. 

Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)

78204-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility.

Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)

78205-1 100 µl
EUR 835
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H

Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)

78205-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H

Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)

78206-1 100 µl
EUR 835
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G

Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)

78206-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G

Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)

78215-1 100 µl
EUR 900
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.

Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)

78215-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.

Human 5-HT1A (Luc) HEK293 Reporter Cell

CHEK-ATF131 2Vials
EUR 14209.6
Description: This gene encodes a G protein-coupled receptor for 5-hydroxytryptamine (serotonin), and belongs to the 5-hydroxytryptamine receptor subfamily. Serotonin has been implicated in a number of physiologic processes and pathologic conditions. Inactivation of this gene in mice results in behavior consistent with an increased anxiety and stress response. Mutation in the promoter of this gene has been associated with menstrual cycle-dependent periodic fevers.

Rev-A3R5-GFP/Luc HIV Reporter Cells

HRC-2 1 vial of 5x10⁶ cells
EUR 1900

Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)

78614-1 100 µl
EUR 860
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)

78614-2 500 µl x 2
EUR 4320
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

Human E-Cadherin, CDH1 Differentiation Reporter (pGreenZeo, virus)

SR10070VA-1 >2 x 10^6 IFUs
EUR 691

NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line

60651 2 vials
EUR 2340
Description: NF-κB luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by 4 copies of NF-kB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.

Rev-CEM-Luc HIV Reporter Cells

HRC-6 1 vial of 5x10⁶ cells
EUR 1500

CD40/NF-κB Reporter (Luc) - HEK293 Stable Cell Line

60626 2 vials
EUR 6825
Description: Recombinant HEK293 cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5). Expression is confirmed by real-time qPCR and Western Blot. This NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD40 ligand, NF-κB transcription factor binds to the DNA response elements to induce transcription of the luciferase gene. _x000D_

AASDHPPT siRNA

20-abx906269
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

AASDHPPT siRNA

20-abx906270
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

AASDHPPT siRNA

20-abx900055
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

Human Alpha-Actin 2, ACTA2 Differentiation Reporter (pGreenZeo, virus)

SR10068VA-1 >2 x 10^6 IFUs
EUR 691

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)

78028-1 100 µl
EUR 900
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.
The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)

78028-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.
The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)

78348-1 100 µl
EUR 900
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).

Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)

78348-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).

AASDHPPT Antibody

34753 100ul
EUR 319

AASDHPPT Antibody

34753-100ul 100ul
EUR 302.4

AASDHPPT Antibody

34753-50ul 50ul
EUR 224.4

AASDHPPT Antibody

1-CSB-PA648080
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against AASDHPPT. Recognizes AASDHPPT from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/40000

AASDHPPT Antibody

1-CSB-PA919003
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against AASDHPPT. Recognizes AASDHPPT from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:50-1:200

AASDHPPT Antibody

1-CSB-PA983505
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against AASDHPPT. Recognizes AASDHPPT from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:50-1:200

AASDHPPT Antibody

E034753 100μg/100μl
EUR 255
Description: Available in various conjugation types.

AASDHPPT Antibody

E19-4134 100μg/100μl
EUR 225
Description: Available in various conjugation types.

AASDHPPT Antibody

E11-16447C 100μg
EUR 225
Description: Available in various conjugation types.

AASDHPPT Antibody

E94909 100μg
EUR 255
Description: Available in various conjugation types.

AASDHPPT Antibody

DF4134 200ul
EUR 420

AASDHPPT Antibody

DF4134-100ul 100ul
EUR 280

AASDHPPT Antibody

DF4134-200ul 200ul
EUR 350

AASDHPPT Antibody

E305241 100ug/200ul
EUR 275
Description: Available in various conjugation types.

AASDHPPT antibody

70R-35912 100 ug
EUR 294
Description: Rabbit polyclonal AASDHPPT antibody

AASDHPPT antibody

70R-2638 50 ug
EUR 467
Description: Rabbit polyclonal AASDHPPT antibody raised against the C terminal of AASDHPPT

AASDHPPT Antibody

ABD4134 100 ug
EUR 525.6

AASDHPPT Antibody

CSB-PA299054- each
EUR 402
Description: A polyclonal antibody against AASDHPPT. Recognizes AASDHPPT from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000

AASDHPPT Antibody

CSB-PA299054-100ul 100ul
EUR 379.2
Description: A polyclonal antibody against AASDHPPT. Recognizes AASDHPPT from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000

AASDHPPT Antibody

1-CSB-PA865121LA01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against AASDHPPT. Recognizes AASDHPPT from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:200-1:1000, IHC:1:20-1:200

AASDHPPT Antibody

8C16447 50ug
EUR 368
Description: AASDHPPT Antibody

AASDHPPT Antibody

GWB-MR269H 50ug Ask for price

BLIV 2.0 Reporter: CMV-Luciferase-EF1a-copGFP Pre-packaged Virus

BLIV511VA-1 >2 x10^6 IFUs
EUR 722

Myc Reporter (Luc) - HCT116 Cell Line (Myc Signaling Pathway)

60520 2 vials
EUR 2175
Description: The Myc Reporter - HCT116 cell line contains the firefly luciferase gene under the control of Myc responsive elements stably integrated into HCT116 cells, a human colon cancer cell line. HCT116 contains a mutated beta-catenin which leads to the accumulation of β-catenin and constitutive activation of downstream Myc that induces the expression of Myc luciferase reporter. The cell line is validated for the inhibition of the expression of Myc luciferase reporter.

GITR / NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line

60546 2 vials
EUR 10175
Description: This cell line expresses a surface human GITR (glucocorticoid-induced TNFR family related gene; TNFRSF18; CD357) and an NF-κB luciferase reporter construct that are stably integrated into the genome of Jurkat T-cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. The cells have been validated using purified human GITRL and anti-GITR neutralizing antibody.

Human MLC-2v Differentiation Reporter (pGreenZeo, Virus), EF1-Neo Marker

SR10011VA-N >2 x 10^6 IFUs
EUR 691

AASDHPPT (Recombinant)

20-abx073160
  • Ask for price
  • Ask for price
  • Ask for price
  • 1 mg
  • 20 ug
  • 5 ug

GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway)

79041 2 vials
EUR 1810
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene.

Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter)

78218-1 100 µl
EUR 835
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.

Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter)

78218-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.

Aasdhppt sgRNA CRISPR Lentivector (Rat) (Target 3)

K6259704 1.0 ug DNA
EUR 184.8

AASDHPPT Rabbit pAb

E2121436 100ul
EUR 225
Description: Available in various conjugation types.

AASDHPPT Rabbit pAb

E2821436 100ul
EUR 225
Description: Available in various conjugation types.

AASDHPPT Rabbit pAb

A4909-100ul 100 ul
EUR 369.6

AASDHPPT Rabbit pAb

A4909-200ul 200 ul
EUR 550.8

AASDHPPT Rabbit pAb

A4909-20ul 20 ul
EUR 219.6

AASDHPPT Rabbit pAb

A4909-50ul 50 ul
EUR 267.6

Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)

78112-1 100 µl
EUR 875
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)

78112-2 500 µl x 2
EUR 4405
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_

Lenti ORF particles, Aasdhppt (GFP-tagged ORF) - Rat aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (Aasdhppt), 200ul, >

RR210095L4V 200 µl Ask for price

Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)

79982-1 100 µl
EUR 1075
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_
The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_

Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)

79982-2 500 µl x 2
EUR 8110
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_
The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_

Aasdhppt sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3456104 1.0 ug DNA
EUR 184.8

AASDHPPT sgRNA CRISPR Lentivector (Human) (Target 3)

K0016004 1.0 ug DNA
EUR 184.8

anti- AASDHPPT antibody

FNab00024 100µg
EUR 658.5
Description: Antibody raised against AASDHPPT

Sox2 SRR2-pGreenFire Response Reporter (pre-packaged virus, EF1-Puro marker)

SR20071-VA-P >2 x 10^6 IFUs
EUR 670

GLP-1R/CRE (Luc) Reporter - HEK293 Recombinant Cell Line

78176 2 vials
EUR 10105
Description: Recombinant HEK293 cells expressing firefly luciferase gene under the control of cAMP response element (CRE) with constitutive expression of human GLP-1R (Glucagon-like peptide 1 receptor; accession number BC113493)._x000D_GLP-1R, a member of the class B family of G protein-coupled receptors (GPCRs) primarily found in pancreatic β cells, is activated by a peptide hormone, glucagon-like peptide 1 (GLP-1) that is secreted from intestinal L-cells after nutrient ingestion. GLP-1R plays an important role in controlling blood sugar level by enhancing glucose-stimulated insulin secretion, so various research efforts have focused on the regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to diabetes.

Lenti ORF particles, Aasdhppt (Myc-DDK-tagged) - Mouse aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (Aasdhppt), 200ul,

MR204387L3V 200 µl Ask for price

Lenti ORF particles, Aasdhppt (GFP-tagged) - Mouse aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (Aasdhppt), 200ul, >10

MR204387L4V 200 µl Ask for price

Lenti ORF particles, AASDHPPT (Myc-DDK tagged) - Human aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (AASDHPPT), 200ul,

RC205091L3V 200 µl Ask for price

Lenti ORF particles, AASDHPPT (mGFP-tagged) - Human aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (AASDHPPT), 200ul, >1

RC205091L4V 200 µl Ask for price

Lenti ORF clone of Aasdhppt (mGFP-tagged) - Mouse aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (Aasdhppt)

MR204387L4 10 µg Ask for price

We mainly discuss the diagnosis and treatment of CMV without intestinal perforation peritonitis.Human cytomegalovirus (HCMV) is a double-stranded DNA virus widely infected humans. Circular RNAs (circRNAs) is a non-coding RNA with most functions remain unknown, and the effects of HCMV infection in the host circRNA productive transcription remains unclear. In this study, we profiled 283 hosts a significant circRNAs amended by the productive infection of HCMV in human embryonic lung fibroblast (helf) by RNA deep sequencing and bioinformatics analysis. Among other things, circSP100, circMAP3K1, circPLEKHM1, and circTRIO validated for transcription and their sequence.

Leave A Comment